# Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Study · id `cardio:ct-nct05682378` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05682378](<https://clinicaltrials.gov/study/NCT05682378>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05682378

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.

## Technical summary

Registry record NCT05682378. Allocation not applicable; no masking; primary purpose treatment. Start 2023-02-10 (actual); primary completion 2032-03-25 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 195 participants (planned count; ClinicalTrials.gov record NCT05682378, source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)
- Started: 2023-02-10 (actual) (ClinicalTrials.gov record NCT05682378, source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)
- Primary completion: 2032-03-25 (anticipated) (ClinicalTrials.gov record NCT05682378, source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)
- Completion: 2032-03-28 (anticipated) (ClinicalTrials.gov record NCT05682378, source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)
- Countries: United States; Argentina; Brazil; Canada; Czechia; France; Germany; Greece; Hungary; Israel; Italy; Jordan; Lebanon; Malaysia; Netherlands; Norway; Poland; Russia; Slovakia; Slovenia; South Africa; Spain; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05682378, source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05682378-2026-09-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
- Acronym: V-PEDS-OLE
- Condition: Heterozygous or Homozygous Familial Hypercholesterolemia
- Intervention (Drug): Inclisiran
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 920178ad5798fe47574ca2ec71c216f859dd98a0238392206f5a06752a353e25
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
